A bill to amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.

Bill 118 s 4741, also known as the Plasma-Derived Products Manufacturer Discount Program Phase-In Act, aims to make changes to title XVIII of the Social Security Act. The main goal of this bill is to provide a gradual implementation process for plasma-derived products under the manufacturer discount program.

Currently, plasma-derived products are subject to a manufacturer discount program, which requires manufacturers to provide discounts on these products to certain federal programs. However, this bill seeks to phase in the application of this program to plasma-derived products over time, rather than implementing it all at once.

The bill does not specify the exact timeline or details of how this phase-in process will occur, but it does outline the general intention to gradually apply the manufacturer discount program to plasma-derived products. This approach is likely aimed at easing the burden on manufacturers and ensuring a smooth transition to the new requirements. Overall, Bill 118 s 4741 is focused on making adjustments to the existing regulations surrounding plasma-derived products and the manufacturer discount program. It is important to note that this bill does not propose any major changes to the overall structure or purpose of the program, but rather seeks to provide a more gradual implementation process for plasma-derived products.